Neumora Therapeutics
kor antagonism has potential for broad neuropsychiatric impact potential to be first novel mechanism approved in in decades | Neumora Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2023
Slide
8 of 32
Related slides by other companies
Alkermes
Investor Day
March 2021
key differentiation parameters support broad potential utility validate molecular design demonstrate anti tumor activity create dosing flexibility support broad potential utility demonstrated selective expansion of and cells demonstrated minimal changes in peripheral regulatory cells in both intravenous and subcutaneous administrations single agent activity observed with combination activity observed in combination with anti both and in hard to treat tumors plans to progress into registration enabling studies only variant in development identified based on safety and anti tumor activity achieved first objective response activity observed with in experienced patients combination activity observed with combination activity observed with multiple agents in preclinical studies may offer dosing flexibility renal cell carcinoma recommended phase dose pharmacodynamic inhibitors net | Alkermes
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights